度拉糖肽与吡格列酮分别联合二甲双胍治疗肥胖2型糖尿病的效果比较

  • 打印
  • 收藏
收藏成功


打开文本图片集

[中图分类号] R587 [文献标志码] A[文章编号] 2096-5532(2025)04-0539-04

doi:10.11712/jms.2096-5532.2025.61.109

LAbstract」ObjectiveTocompare the efectsofdulaglutide and pioglitazone whencombined with metforminon glucoseand lipidmetabolism,vascularendothelialfunction,andmicroinflammatorystateinobese patientswithtype2diabetesmelitus. MethodsWerandomized148obesepatients withtype2diabetesadmited toourhospitalfromOctober2022toDecember2023 into groupAandgroupB,with74cases ineach group.GroupAwastreated with dulaglutide injectioncombined withmetformin hydrochloride,while groupBwas treated with pioglitazonehydrochloridecombined withmetforminhydrochloride.Thetwo groups werecompared intermsofchangesinglucoseandlipidmetabolism,vascularendothelialfunction,andmicroinflammatoryindicatorsbeforeandaftertreatment.ResultsAftertreatment,bothgroupsshowedsignificantlydecreasedlevelsoffastingblood glu cose,totalcholesterol,low-densitylipoproteincholesterol(LDL-C),triglycerides(TG),glycated hemoglobin(GHb),andfree fattyacids(FFA) (t=5.298-15.947,P<0.05) ,high density lipoprotein cholesterol were higher than before treatment( Ψt=ΨΨ 4.492,5.223,P<0.05) ;significantly reduced levels of vascular endothelial growth factor(VEGF)and endothelin-1(ET-1)( ℓt= (20号 6.652-97.702,P<0.05) ;and significantly increased nitric oxide(NO) levels ( :t=17.173,23.352,P<0.05⟩ and significantly decreased levels of interleukin-6 and high-sensitivity C-reactive protein(hs-CRP) t=8.273-28.190,P<0.05) . The two groups differed significantlyinthechangesinGHb,LDL-C,TG,FFA,VEGF,NO,ET-1,and hs-CRPbefore and after treatment( Ψt=ΨΨ 3.053-5.716 , P<0.05 ).ConclusionCompared with pioglitazone hydrochloride combined with metformin,dulaglutide combinedwith metformincanbeterimprove glucoseandlipid metabolism,vascularendothelialfunction,and microinflammatorystatus in obese patients with type 2 diabetes.

[Key words]glucagon likepeptide-lreceptoragonist;pioglitazone;dulaglutide;metformin;type2diabetes;treatmentout come

中国成人2型糖尿病的患病率为 11.6% ,在肥胖和超重群体中患病率更高,分别达到 18.5% 和12.8%[1-2] 。(剩余6356字)

monitor
客服机器人